May Non-antipsychotic drugs improve cognition of schizophrenia patients?

Research output: Contribution to journalArticle

Abstract

Rationale: Cognitive impairment in schizophrenia patients is associated with poor outcome and it represents one of main challenges of pharmacological treatment. Unfortunately, second-generation antipsychotics have not yielded the expected results in the improvement of these symptoms. Objective: The purpose of the present review paper is to summarize and discuss the available data about the efficacy of non-antipsychotic drugs in the treatment of cognitive symptoms of schizophrenia. Methods: A research in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while studies with schizoaffective patients have been excluded. Results: Several non-antipsychotic compounds have been tested with the purpose to improve cognitive symptoms in schizophrenia patients, but no molecule has a significant pro-cognitive activity. Conclusion: Available data do not support the superiority of non-antipsychotic drugs vs. placebo for cognitive enhancement in schizophrenia. Preliminary results indicate mirtazapine, mianserine, lamotrigine, tandospirone, cyproheptadine, valacyclovir and omega-3 fatty acids as the most promising compounds, however no definitive conclusions can be drawn in the light of small sample size studies.

Original languageEnglish
Pages (from-to)41-50
Number of pages10
JournalPharmacopsychiatry
Volume48
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Cognition
Schizophrenia
Neurobehavioral Manifestations
valacyclovir
Pharmaceutical Preparations
Cyproheptadine
Omega-3 Fatty Acids
Sample Size
Antipsychotic Agents
Placebos
Databases
Pharmacology
Therapeutics
Research

Keywords

  • cognition
  • psychopharmacology
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

May Non-antipsychotic drugs improve cognition of schizophrenia patients? / Buoli, M.; Altamura, A. C.

In: Pharmacopsychiatry, Vol. 48, No. 2, 2015, p. 41-50.

Research output: Contribution to journalArticle

@article{356690c98d5141e98c8ad6f898f22aa0,
title = "May Non-antipsychotic drugs improve cognition of schizophrenia patients?",
abstract = "Rationale: Cognitive impairment in schizophrenia patients is associated with poor outcome and it represents one of main challenges of pharmacological treatment. Unfortunately, second-generation antipsychotics have not yielded the expected results in the improvement of these symptoms. Objective: The purpose of the present review paper is to summarize and discuss the available data about the efficacy of non-antipsychotic drugs in the treatment of cognitive symptoms of schizophrenia. Methods: A research in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while studies with schizoaffective patients have been excluded. Results: Several non-antipsychotic compounds have been tested with the purpose to improve cognitive symptoms in schizophrenia patients, but no molecule has a significant pro-cognitive activity. Conclusion: Available data do not support the superiority of non-antipsychotic drugs vs. placebo for cognitive enhancement in schizophrenia. Preliminary results indicate mirtazapine, mianserine, lamotrigine, tandospirone, cyproheptadine, valacyclovir and omega-3 fatty acids as the most promising compounds, however no definitive conclusions can be drawn in the light of small sample size studies.",
keywords = "cognition, psychopharmacology, schizophrenia",
author = "M. Buoli and Altamura, {A. C.}",
year = "2015",
doi = "10.1055/s-0034-1396801",
language = "English",
volume = "48",
pages = "41--50",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "2",

}

TY - JOUR

T1 - May Non-antipsychotic drugs improve cognition of schizophrenia patients?

AU - Buoli, M.

AU - Altamura, A. C.

PY - 2015

Y1 - 2015

N2 - Rationale: Cognitive impairment in schizophrenia patients is associated with poor outcome and it represents one of main challenges of pharmacological treatment. Unfortunately, second-generation antipsychotics have not yielded the expected results in the improvement of these symptoms. Objective: The purpose of the present review paper is to summarize and discuss the available data about the efficacy of non-antipsychotic drugs in the treatment of cognitive symptoms of schizophrenia. Methods: A research in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while studies with schizoaffective patients have been excluded. Results: Several non-antipsychotic compounds have been tested with the purpose to improve cognitive symptoms in schizophrenia patients, but no molecule has a significant pro-cognitive activity. Conclusion: Available data do not support the superiority of non-antipsychotic drugs vs. placebo for cognitive enhancement in schizophrenia. Preliminary results indicate mirtazapine, mianserine, lamotrigine, tandospirone, cyproheptadine, valacyclovir and omega-3 fatty acids as the most promising compounds, however no definitive conclusions can be drawn in the light of small sample size studies.

AB - Rationale: Cognitive impairment in schizophrenia patients is associated with poor outcome and it represents one of main challenges of pharmacological treatment. Unfortunately, second-generation antipsychotics have not yielded the expected results in the improvement of these symptoms. Objective: The purpose of the present review paper is to summarize and discuss the available data about the efficacy of non-antipsychotic drugs in the treatment of cognitive symptoms of schizophrenia. Methods: A research in the main database sources has been performed to obtain a comprehensive overview. Studies with different methodologies (open and double-blinded) have been included, while studies with schizoaffective patients have been excluded. Results: Several non-antipsychotic compounds have been tested with the purpose to improve cognitive symptoms in schizophrenia patients, but no molecule has a significant pro-cognitive activity. Conclusion: Available data do not support the superiority of non-antipsychotic drugs vs. placebo for cognitive enhancement in schizophrenia. Preliminary results indicate mirtazapine, mianserine, lamotrigine, tandospirone, cyproheptadine, valacyclovir and omega-3 fatty acids as the most promising compounds, however no definitive conclusions can be drawn in the light of small sample size studies.

KW - cognition

KW - psychopharmacology

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84924106260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924106260&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1396801

DO - 10.1055/s-0034-1396801

M3 - Article

C2 - 25584772

AN - SCOPUS:84924106260

VL - 48

SP - 41

EP - 50

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 2

ER -